Volufiline Searches Up 1,698%, the Ingredient Dates to 2010

What is the signal?

TheIndustry.beauty reported on 16 October 2026 that searches for Volufiline on Cult Beauty's site rose 1,698% year on year. In the same data, searches for "The Ordinary Volufiline" rose 2,531% as of 8 October 2026, and PDRN searches rose 201.5%. One ingredient name climbed by a four-digit rate in a year.

The product behind the searches can be named. It is The Ordinary's Volufiline 92% + Pal-Isoleucine 1% plumping serum. Its product page addresses areas that look hollow — under-eyes, cheeks, smile lines, temples — and describes a water-free, alcohol-free, oil-free, silicone-free anhydrous format. The US site lists it at $21.40 for 15ml, applied after moisturiser with a patch test advised first. The same page states that Volufiline is a trademark of Sederma Inc. and that neither DECIEM nor The Ordinary is affiliated with Sederma.

The supply side is documented on the supplier's page. Croda Personal Care lists Volufiline's INCI as hydrogenated polyisobutene with Anemarrhenae asphodeloides root extract, a liquid that stimulates fat-cell formation for a plumping effect, and notes that it is a cosmetic ingredient for expert formulation rather than a finished product.

The age of the evidence is the point of this article. The Cosmetics & Toiletries piece covering Sederma's launch of Volufiline dates to around 2010, when the use was bust and décolletage contouring. It was described as a non-hormonal ingredient that stimulates adipocyte differentiation, with the mechanism studied in vitro through DNA array gene analysis. The "up to 8.4% volume increase" figure circulating in consumer copy could not be traced to a study design, population or duration, and no 2026 trade coverage of the ingredient surfaced either.

A note on scope. The 1,698% and 2,531% figures are one retailer's own on-site search counts, not sales. A year-on-year rate rises easily when the base period is small, and the two numbers come from different search terms — an ingredient name and a product name — so they cannot be compared directly. The countries and user mix behind the data were not disclosed. This article therefore treats the figures only as a demand signal that an ingredient name has entered consumer language, not as evidence of market size or efficacy.

One sentence translates into development. The demand is current and both the ingredient and its evidence are from 2010, so closing that gap in the product specification comes first.

1. 92% is the base, not an addition

Reading "92% Volufiline" as an active concentration leads the judgement astray. The INCI on Croda's page shows a liquid of hydrogenated polyisobutene carrying Anemarrhena root extract. The first of those is a non-polar synthetic hydrocarbon, and at 92% it leaves almost no room for a water phase. The Ordinary's product arriving as a water-free anhydrous serum looks less like a positioning choice than a consequence of that loading.

Choosing an anhydrous format swaps out the whole checklist. Viscosity change and oxidative stability move ahead of emulsion stability, and a formula without a water phase starts from different premises for its preservation rationale. Add fragrance or colour and solubility in an oil base and discolouration have to be assessed separately. Added after the formula is locked, these items do not reschedule the project — they rewrite the formula.

Sensory feel arrives even earlier. A high load of non-polar emollient leaves shine and residue, and makeup applied over it can slip. If the under-eye is an application area, eye-area irritation and visual haze belong in the use-test protocol, and whether the product goes before or after moisturiser is also settled by feel. If it will be explained as a product for hollow areas, local application needs a matching dispenser — and that is a container decision, not a formulation one.

Fill size has to be decided alongside. The reference product is 15ml. A small fill for local application lowers the share of cost taken by the contents and raises the share taken by container, label and secondary packaging, and an anhydrous oil-type formula returns different container compatibility results than a water-based one, so plasticiser migration and gasket swelling need separate checks. Choose the container first and fit the formula to it, and those checks get pushed to the back.

• Whether "92%" is written into the brief as a base ratio rather than an active concentration
• Whether the preservation rationale, oxidative stability and viscosity items were re-set for an anhydrous premise
• Whether shine, residue and makeup slip are in the use-test protocol
• Whether eye-area irritation and visual haze testing are designed in for under-eye application
• Whether container compatibility (plasticiser migration, gasket swelling) was checked for an anhydrous oil type

2. The evidence file stops at in vitro

Stack the confirmed evidence in layers. At the top is the supplier's description: Croda's page says the ingredient stimulates fat-cell formation for a plumping effect. Below it is the study design recorded in the 2010 launch coverage: the mechanism was examined in vitro through DNA array gene analysis. Below that sits the "up to 8.4%" figure, which circulates as consumer copy while its underlying study design, population and duration could not be verified. No independently conducted clinical results surfaced within the search scope.

The product conclusion from that structure is clear. A cell-level result for a raw material cannot be transcribed as a volume increase in a treated area for a finished product. What an ingredient did in cells and what changed when a person applied a finished product to their face are different grades of data, and loading the ingredient at 92% does not join them automatically. No recommended use level was available on the supplier's page, so there is no published material supporting the high loading itself.

Putting this ingredient on the front of the pack therefore means budgeting a finished-product study at the planning stage. The difficulty is the endpoint. Unlike hydration, elasticity or roughness, "volume in a hollow area" is awkward to measure reproducibly, and more so when the area is as small as the under-eye. It is safer to settle which instrument measures what, over how many weeks, on how many subjects, before the formula is locked. Without a measurement design, results arrive and no usable sentence remains.

Claim language has to follow the same layers. With no finished-product study, what can be written is a factual statement of the ingredient and its level; sentences that set up comparison with an aesthetic procedure come after that data exists. Noting beside each claim whether the evidence is raw-material or finished-product data means not re-litigating everything later when copy is adjusted market by market.

• Whether raw-material in vitro data and finished-product study data are distinguished in the brief
• Whether circulating figures such as "up to 8.4%" were left out for lack of a traceable source
• Whether the absence of a published recommended use level is reflected in the loading decision
• Whether the instrument, duration and panel size for volume endpoints were set before the formula was locked
• Whether each claim is marked with the grade of evidence behind it

3. A single supplier ties up both supply and trademark

Volufiline is a Sederma (Croda) ingredient and the name itself is a trademark. The reference product page carries a note that Volufiline is a trademark of Sederma Inc. and that DECIEM and The Ordinary are not affiliated with Sederma. A brand that wants the name on its product or detail page has to settle the trademark position first, and that runs separately from formulation work.

The name also splits in two. Consumers search for "Volufiline," while the ingredient list carries hydrogenated polyisobutene and Anemarrhenae asphodeloides root extract. Without an explanation on the detail page connecting the two, a shopper who checks the ingredient list reads it as the ingredient being absent. Conversely, if the trademark cannot be used, it is better to build the brief around Anemarrhena root extract as the claim word from the start.

Cost and supply are exposed more than usual because of the loading. At 92% or anything near it, this ingredient accounts for most of the formula, so product cost and lead time effectively follow one supplier's terms. Allocation, minimum purchase units and lot changes on a single-source material feed straight into the production schedule, so confirm the material's own delivery and minimum purchase terms before requesting quotations. The figure that comes back sets the floor for the finished-product volume plan.

Keep a lower loading on the table too. 92% is one brand's decision; a lower level opens up water-based or emulsion formats, and with them a wider choice of feel and container. The trade-off is that with no published recommended use level, there is also no documentation for what a reduced loading should deliver. Writing that trade-off into the brief is how you avoid requesting quotations twice.

• Whether the right to use the trademark on the product name and detail page was confirmed
• Whether the gap between the ingredient-list wording and the claim wording is handled in the detail page design
• Whether the material's delivery and minimum purchase terms were confirmed before the finished-product quotation
• Whether the schedule impact of lot changes on a single-source material was checked
• Whether the trade-off between high and low loading is written into the brief

4. The 2010 use and today's use are different

Same ingredient, different area. The use at its 2010 introduction was bust and décolletage contouring; the product driving today's searches talks about facial areas such as the under-eye and the temples. Change the area and the safety assessment and use-test design change with it, as do the per-use dose and the frequency. A product spread broadly over the body and one placed in a small amount under the eye present different exposure conditions even from the same formula.

Container and directions follow the area as well. A pump for broad coverage and a dropper or applicator for local use deliver different doses per application, and once the dose changes, the period of use and the fill size change. If the eye area is listed, the applicator material and tip shape enter the irritation assessment too. Directions written as an area and an amount, rather than "the whole face," also match the conditions actually tested.

The biggest change is what the product is compared against. The reporting indicates that interest in this ingredient comes from a wish to fill hollow areas without a procedure. When a shopper places the product beside an aesthetic treatment, expectations rise to a level a cosmetic product struggles to meet, and that gap returns as refunds and complaints. With no independent clinical evidence confirmed, this matters more, not less.

Expectations have to be set in the specification before the detail page. Write the application area narrowly, state the per-use dose and the recommended period, and use only data confirmed under those conditions. Narrowing this way looks like a weaker claim, but building finished-product data under narrowed conditions ends up leaving more sentences you can actually use.

• Whether the application area is written narrowly in the spec with a per-use dose
• Whether the safety assessment and use-test design were re-set for the changed area
• Whether container and fill size were decided together on the basis of dose per application
• Whether applicator material and shape are in the irritation assessment for eye-area use
• Whether expectations against aesthetic procedures are limited by the spec and the directions

The first question for the brief

Instead of writing "develop a Volufiline product," change one line: is this product anhydrous? Because the ingredient's base is hydrogenated polyisobutene, loading it high settles the format immediately. Raising the preservation rationale, oxidative stability, sensory feel and container compatibility together before the formula is locked costs less than taking them one at a time.

The second thing to write is the layer of evidence. What is confirmed today runs from the supplier's description to a 2010 in vitro gene analysis, and the widely circulated "up to 8.4%" is copy whose study design cannot be verified. So decide the sentence you want to make about the finished product, and write the measurement endpoints, duration and panel size that would support it into the brief as numbers. Without a measurement design, a study leaves no usable sentence.

The last is area and quantity. Write the application area narrowly, as under-eye rather than face, and the dose and fill size follow; once dose and fill are set, the container is set. And for a product where this ingredient is most of the formula, the material's minimum purchase terms set the floor for the finished-product volume plan. Confirm the material's lead time and minimum purchase terms before the finished-product quotation.